StockData

Aspire-Lakewood vs Gelteq

ASBP and GELS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ASBP and GELS compare

Aspire-Lakewood scores higher on the StockData Score (2 against 0 for Gelteq), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricASBPGELS
Size and price
Market cap$11.8M–
Share price$8.41$0.380
Change, 1 year95.9%−64.1%
Beta (5Y)–2.50
StockData Score
Total score2 (better)0
Valuation score1 (better)0
Growth score00
Performance score00
Health score1 (better)0
Dividend score00
Valuation
P/S121×–
P/B1.0×–
Profitability
Gross margin−25.0%30.3% (better)
Operating margin−7495%−3318% (better)
Net margin−11314%–
FCF margin–−3335%
Return on equity−1032%–
Financial health
Interest coverage−0.8× (better)−2.8×
Current ratio7.99 (better)0.09
Altman Z-score−0.05–
Piotroski F-score3–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by insiders1.4%14.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.